Protein / target
Glutamate-gated chloride channel
Protein at a glance
Biological role
Extracellular ligand-gated monoatomic ion channel
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Subcellular location
Domains and Gene Ontology detail (4)Hide
Domains & features
Gene Ontology
- Cplasma membrane
- Fextracellular ligand-gated monoatomic ion channel activity
- Ftransmembrane signaling receptor activity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Ion channel gating
- ·extracellular ligand-gated monoatomic ion channel activity
Ligand-gated signalling
- ·extracellular ligand-gated monoatomic ion channel activity
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Glutamate-gated chloride channel modulator
Indicated for Helminthiasis, Onchocerciasis, Rosacea
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: IVERMECTIN (ANDA218509)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.